A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease

Theresa Hahn(Roswell Park Comprehensive Cancer Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Mustafa Beneklı, Meir Wetzler, Maria R. Baer(University of Maryland, Baltimore), River Chun‐Wai Wong(Roswell Park Comprehensive Cancer Center), Kirsten B. Moysich(American Cancer Society), Arif Alam(Roswell Park Comprehensive Cancer Center), B Bambach(Women & Children's Hospital of Buffalo), Arthur M. Michalek(Roswell Park Comprehensive Cancer Center), Joanne Becker(Roswell Park Comprehensive Cancer Center), M. S. Czuczman(Roswell Park Comprehensive Cancer Center), Andrew Hyland(Roswell Park Comprehensive Cancer Center)
Bone Marrow Transplantation
January 24, 2005
10.1038/sj.bmt.1704789
Cited by 27

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764